Yash Doshi

Congratulations on a good set of numbers. Regarding Nor-UDCA, if you look quarter-on- quarter in Q1 FY27, your domestic revenue has dipped a bit. So -- what's the exact reason for it? Because I think we launched 6 months ago, ideally the product would scale up, but this is a small blip.

Understood. And another question was regarding the API division, which grew at 16% and was led by your specialty CDMO. So I just wanted to check whether it was contributed more by the normal innovative CDMO portfolio or the polymer division?

And just last question. This quarter, we onboarded 2 Japanese customers, right? I think it was late-stage projects. So can you talk about the background of the clients, whether it's a big pharma or biotech? And what can be the opportunity size?